[go: up one dir, main page]

WO2010081443A3 - Formes galéniques d'inhibiteurs de tyrosine kinase - Google Patents

Formes galéniques d'inhibiteurs de tyrosine kinase Download PDF

Info

Publication number
WO2010081443A3
WO2010081443A3 PCT/CZ2010/000002 CZ2010000002W WO2010081443A3 WO 2010081443 A3 WO2010081443 A3 WO 2010081443A3 CZ 2010000002 W CZ2010000002 W CZ 2010000002W WO 2010081443 A3 WO2010081443 A3 WO 2010081443A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage forms
kinase inhibitors
tyrosine kinase
inhibitors
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CZ2010/000002
Other languages
English (en)
Other versions
WO2010081443A2 (fr
Inventor
Vladimir Kral
Josef Jampilek
Jaroslav Havlicek
Hana Brusova
Tomas Pekarek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Publication of WO2010081443A2 publication Critical patent/WO2010081443A2/fr
Anticipated expiration legal-status Critical
Publication of WO2010081443A3 publication Critical patent/WO2010081443A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Des co-cristaux d'inhibiteurs de tyrosine kinases, spécialement de mésylate d'Imatinib, se sont révélés une forme adaptée d'API dans des formes galéniques, classiques comme à libération contrôlée, pour des médicaments de seconde génération. Des complexes d'inhibiteurs de kinase avec des polysaccharides fonctionnalisés forment des dispersions solides adaptées aux applications pharmaceutiques.
PCT/CZ2010/000002 2009-01-13 2010-01-13 Formes galéniques d'inhibiteurs de tyrosine kinase Ceased WO2010081443A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20090008A CZ20098A3 (cs) 2009-01-13 2009-01-13 Lékové formy inhibitoru tyrosinových kináz
CZPV2009-8 2009-01-13

Publications (2)

Publication Number Publication Date
WO2010081443A2 WO2010081443A2 (fr) 2010-07-22
WO2010081443A3 true WO2010081443A3 (fr) 2011-10-27

Family

ID=42338099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2010/000002 Ceased WO2010081443A2 (fr) 2009-01-13 2010-01-13 Formes galéniques d'inhibiteurs de tyrosine kinase

Country Status (2)

Country Link
CZ (1) CZ20098A3 (fr)
WO (1) WO2010081443A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2009570A3 (cs) * 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
CZ302789B6 (cs) * 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
CN102188365B (zh) * 2011-05-11 2012-12-05 中山大学 一种难溶性药物共晶固体分散体及其制备方法
ES2946549T3 (es) * 2012-01-13 2023-07-20 Xspray Pharma Ab Publ Composición farmacéutica de nilotinib
WO2013186726A2 (fr) * 2012-06-15 2013-12-19 Basf Se Cristaux à plusieurs composants comprenant du dasatinib et des agents de formation de cocristaux choisis
CA2877030A1 (fr) * 2012-06-22 2013-12-27 Basf Se Cristaux multicomposants comprenant du mesilate d'imatinib et des agents de co-cristallisation choisis
WO2014016848A2 (fr) * 2012-07-24 2014-01-30 Laurus Labs Private Limited Formes solides d'inhibiteurs de tyrosine kinase, procédé pour leur préparation et leur composition pharmaceutique
KR20150068483A (ko) 2012-10-19 2015-06-19 바스프 에스이 닐로티닙 및 선택된 공-결정 형성제를 포함하는 다성분 결정질 시스템
CN103800334B (zh) * 2012-11-07 2016-12-21 北大方正集团有限公司 甲磺酸伊马替尼的药物组合物及其制备方法
EP3024830A2 (fr) 2013-07-25 2016-06-01 Basf Se Sels de dasatinib se présentant sous forme cristalline
KR101831535B1 (ko) * 2013-07-25 2018-02-22 바스프 에스이 무정형 형태의 다사티닙 염
CA2838585A1 (fr) * 2013-10-18 2015-04-18 Hari Babu Matta Sel de sunitinib d'acide ascorbique
EP2937346A1 (fr) * 2014-04-24 2015-10-28 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Co-cristaux de lapatinib
WO2016058081A1 (fr) 2014-10-16 2016-04-21 Apotex Inc. Formes solides du chlorhydrate de nilotinib
WO2016096999A1 (fr) 2014-12-19 2016-06-23 Synthon B.V. Composition pharmaceutique contenant du géfitinib
PT109445B (pt) * 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose
IT201700006157A1 (it) 2017-01-20 2018-07-20 Cerbios Pharma Sa Co-cristalli di un composto antitumorale
IT201700006145A1 (it) * 2017-01-20 2018-07-20 Cerbios Pharma Sa Co-cristallo di un composto antitumorale
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
WO2021138391A1 (fr) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Composés d'indazole
EP4093379A1 (fr) 2020-01-24 2022-11-30 Nanocopoeia LLC Dispersions solides amorphes de dasatinib et leurs utilisations
EP4096791A1 (fr) 2020-01-31 2022-12-07 Nanocopoeia LLC Microparticules de nilotinib amorphe et leurs utilisations
CA3181361A1 (fr) 2020-04-30 2021-11-04 Nanocopoeia, Llc Comprime a desintegration orale comprenant une dispersion solide amorphe de nilotinib
WO2022000265A1 (fr) * 2020-06-30 2022-01-06 天津理工大学 Cocristaux d'axitinib et d'acide glutarique, et leur procédé de préparation
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
CN115417812B (zh) * 2022-08-05 2024-04-05 天津大学 一种阿西替尼-烟酰胺共晶及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027600A2 (fr) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Compositions d'imatinib
WO2008112722A2 (fr) * 2007-03-12 2008-09-18 Dr. Reddy's Laboratories Ltd. Mésylate d'imatinib
EP2000139A1 (fr) * 2007-06-07 2008-12-10 Novartis AG Formes amorphes stabilisées du mésylate de l'imatinib

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027600A2 (fr) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Compositions d'imatinib
WO2008112722A2 (fr) * 2007-03-12 2008-09-18 Dr. Reddy's Laboratories Ltd. Mésylate d'imatinib
EP2000139A1 (fr) * 2007-06-07 2008-12-10 Novartis AG Formes amorphes stabilisées du mésylate de l'imatinib

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BENI ET AL: "Cyclodextrin/imatinib complexation: Binding mode and charge dependent stabilities", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 30, no. 2, 26 January 2007 (2007-01-26), pages 167 - 174, XP005738249, ISSN: 0928-0987, DOI: DOI:10.1016/J.EJPS.2006.10.008 *
LEUNER C ET AL: "Improving drug solubility for oral delivery using solid dispersions", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 50, no. 1, 3 July 2000 (2000-07-03), pages 47 - 60, XP004257179, ISSN: 0939-6411, DOI: DOI:10.1016/S0939-6411(00)00076-X *
PEDDY VISHWESHWAR ET AL: "Pharmaceutical Co-Crystals", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 95, no. 3, 1 January 2006 (2006-01-01), pages 499 - 516, XP002492464, ISSN: 0022-3549, DOI: DOI:10.1002/JPS.20578 *

Also Published As

Publication number Publication date
CZ20098A3 (cs) 2010-07-21
WO2010081443A2 (fr) 2010-07-22

Similar Documents

Publication Publication Date Title
WO2010081443A3 (fr) Formes galéniques d'inhibiteurs de tyrosine kinase
WO2011031896A3 (fr) Inhibiteurs de pi3 kinase et leurs utilisations
HK1220184A1 (zh) 用於治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物
WO2008138755A3 (fr) Compositions pharmaceutiques pour des médicaments solubles de façon médiocre
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
MY189427A (en) Pyrazolyl quinoxaline kinase inhibitors
PH12012502334A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
IN2012DN02469A (fr)
SG171542A1 (en) Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin
WO2009151910A3 (fr) Produit de combinaison d'un inhibiteur de tyrosine kinase de récepteur et d'un inhibiteur d'acide gras synthase pour le traitement du cancer
WO2010123919A3 (fr) Inhibiteurs pipéridiniques de la janus kinase 3
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
WO2012122011A3 (fr) Amino-quinoléines en tant qu'inhibiteurs de kinase
WO2010120994A3 (fr) Composés d'uréido-aryl-pyrimidine et de carbamoylaryl-morpholino-pyrimidine, leur utilisation comme inhibiteurs de la kinase mtor et de la kinase pi-3, et leur synthèse
WO2011073341A3 (fr) Dispersions de polymères
WO2011106248A3 (fr) Inhibiteurs triméthoxyphényles de la tyrosine kinase
NZ705578A (en) Coated pharmaceutical composition containing regorafenib
MY161461A (en) Akt and p70 s6 kinase inhibitors
WO2011056511A3 (fr) Stimulateurs de la guanylate cyclase soluble à base de 4,6-diaminopyrimidine
WO2014076712A3 (fr) Dispersion solide de chlorhydrate de lurasidone
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
ZA201200026B (en) Novel (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide derivatives,preparation thereof,and pharmaceutical use thereof as akt(pkb) phosphorylation inhibotors
WO2009114461A3 (fr) Formes pharmaceutiques d'angiotensine (1-7) et leur utilisation
HK1202435A1 (en) Dosage regimen for a pi-3 kinase inhibitor
WO2009113092A3 (fr) Procédé de préparation du chlorhydrate de proguanil

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10714557

Country of ref document: EP

Kind code of ref document: A2